Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NMCNK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ZV0203
|
|||||
| Synonyms |
Recombinant anti-EGFR monoclonal antibody- DUO5 conjugate; ZV 0201; ZV 0203; ZV-0201; ZV-0203; ZV0201; ZV0203; ZV0203-ADC; ADC-2122; ADC 2122; ADC2122
Click to Show/Hide
|
|||||
| Organization |
Zhejiang Hisun Pharmaceutical Co., Ltd.; Zhejiang Zova Biotherapeutics Inc
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Pertuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Duostatin 5
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Pip-Val-Cit
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
